The primary therapeutic benefit of Дистрептаза is commonly used as a supplementary agent for localized treatment, is relevant in addressing the symptoms associated with persistent structural and purulent remnants of inflammation within the lower pelvis and perirectal area. The enzyme combination is relevant for helping manage symptoms linked to the presence of clotted material and purulent accumulations, which plays a role in managing its key uses.

This medicine is commonly used to manage the structural consequences of conditions like Pelvic Inflammatory Disease (PID), perirectal abscesses, and acute haemorrhoidal disease, and is often applied during the postoperative period following abdominal or gynecological surgeries. In these situations, the support provided is relevant for easing pronounced symptoms, including intense local pain syndrome and swelling, contributing to a more manageable experience during managing these challenging manifestations. The overall application provides support that helps ease the overall symptom load associated with chronic inflammation and may assist with maintaining functional stability.

---

“The support provided is relevant for easing pronounced symptoms.”

---

Quick Fact: Relief for Hardened Inflammatory Infiltrates

This medication is often applied when symptoms are driven by persistent, hardened masses or infiltrative lesions. This medication is relevant for managing symptoms related to persistent, hardened masses or infiltrative lesions.

Regulatory References

1. NIH MeSH entry for Streptodornase and Streptokinase

The eligibility for using Дистрептаза (Streptokinase/Streptodornase) is defined by regulatory authorities based on contraindications, age, and physiological status. The medicine is primarily intended for adults.

Contraindicated Populations (Must Not Use)

Category	Official Regulatory Statement
Allergies	Patients with hypersensitivity to the active substances or any excipients.
Reproductive Status	Pregnant women and breastfeeding women.
Local Conditions	Areas with fresh surgical sutures, wounds covered with a fresh scab, or recent haemorrhage (bleeding event).

Eligibility Rules and Restrictions

• Pediatric Use: Use in children and adolescents has not been established due to a lack of safety and efficacy data in these age groups.
• Co-Treatment: The product should not be used concurrently with anticoagulant drugs (blood thinners).
• Organ Function: No dosage adjustment is necessary for patients with hepatic impairment, but no information on adjustment is available for those with renal impairment.

Regulatory documents limit eligibility to adults and explicitly prohibit use in specific clinical and physiological states to ensure safe use, particularly considering the medicine’s enzymatic activity.

The interaction profile for Дистрептаза is strictly governed by prohibitions documented in regulatory sources regarding co-administration with specific substance categories.

Documented Contraindicated Combinations

The official prescribing information classifies the co-administration of Дистрептаза with two main substance groups as contraindicated, meaning simultaneous use is prohibited.

• Anticoagulant Drugs: Co-administration with anticoagulant medicinal products, such as those used to inhibit blood clotting, is strictly prohibited. This is due to a pharmacodynamic interaction that results in an additive effect, leading to a formally documented increased risk of local bleeding.
• Calcium Salts: A categorical restriction also applies to medicinal products containing Calcium salts, which must not be used at the same time as Дистрептаза.

Pharmacokinetic and Population-Specific Notes

The interaction profile does not document common metabolic interactions involving cytochrome P450 (CYP) enzymes or drug transporters. Crucially, regulatory documents note that because Дистрептаза is not metabolized in the liver, there are no specific interaction cautions related to dose adjustment or heightened risk for patients with underlying hepatic or renal impairment. No interactions are documented concerning timing separation requirements or co-administration with food, alcohol, or herbal products.

The mechanism of Дистрептаза (Streptokinase/Streptodornase) is based on a localized dual-enzymatic action that targets the major physical components of fibrin and purulent accumulations within the tissue.

Molecular Activation of Localized Fibrinolysis

The component Streptokinase exerts its effect by acting as an activator within the body's natural fibrinolytic system. It achieves this by binding to the inactive protein, Plasminogen, which generates a complex that converts other Plasminogen molecules into the active enzyme, Plasmin. This activated Plasmin then chemically dismantles the cross-linked fibrin polymers that form the rigid, structural matrix of localized clots and fibrinous accumulations.

Enzymatic Liquefaction of Purulent Cellular Debris

The second component, Streptodornase, functions as a highly specific enzyme that targets the viscous material found within purulent masses. It acts as an Endodeoxyribonuclease that hydrolyzes the long chains of DNA and deoxyribonucleoprotein released from dead cells, significantly reducing the viscosity of the hydrolyzed substrate mass.

Synergy for Comprehensive Enzymatic Debridement

These two independent mechanisms work in synergy to achieve comprehensive enzymatic breakdown of the structural components: fibrinolysis clears the protein scaffolding, while the liquefaction clears the cellular content. This coordinated action transforms the rigid, viscous material into a fluid state, facilitating its physiological removal and leading to the dismantling of the localized structure.

Instruction Map: How to use Дистрептаза — Official Administration Guidelines

Administration Scope

Entity	Detail
Route of administration	Rectal (The suppository must be inserted deep into the rectum).
Dosing schedule	Dosage is phased and dependent on the specific course duration: Average total course involves 8 to 18 suppositories over 7 to 10 days.
	For Serious Conditions: 3 suppositories daily for 3 days, reducing sequentially to 2 daily for 3 days, and finally 1 daily for 3 days.
	For Less Serious Conditions: A shorter course may involve 2 suppositories daily for 3 days, followed by 1 daily for 4 days.
Timing in relation to meals (if applicable)	Not specified; timing is defined by the necessary daily frequency (once, twice, or three times daily).
Preparation requirements (if applicable)	The suppository must be removed from its protective blister packaging immediately prior to administration.
Age-group administration rules	Children/Adolescents: Safety and dose have not been established. Hepatic Impairment: No dosage adjustment is necessary as the product is administered rectally and is not metabolized by the liver.
Special procedural conditions	The product should not come into contact with wounds covered by a fresh scab or surgical sutures.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Local/Topical via Rectal Suppository.
Frequency pattern	Daily, following a defined schedule of one, two, or three times per day based on the treatment phase.
Use-context constraints	Administration is prohibited at sites with recent wound closure or scabs, and is not defined for use in patients under 18 years old.

Resulting Procedural Structure

Official step sequence:

• Remove the suppository from its protective packaging.
• Insert the suppository deep into the rectum.
• Administer the daily dose according to the specific frequency mandated for that phase of the course.

Connection to the Overall Use Protocol

The official instructions establish a standardized, localized protocol using the rectal route for the 15,000 IU/1,250 IU combination. This protocol is defined by a phased schedule of decreasing daily frequency over a short, time-bound course, typically lasting between 7 and 10 days, which defines the precise administrative framework for the product.

Research evidence / Overview of studies for Дистрептаза

Evidence for use in Acute Hemorrhoidal Disease

Research has examined the enzyme combination through structured clinical trials, including Randomized Controlled Trials (RCTs), where its use was evaluated in comparison with other local treatments or non-active preparations. These studies were conducted during periods of increased symptom activity and typically involved adult patients presenting with acute symptoms. Research explored outcomes related to physical discomfort and changes in localized masses. The findings describe patterns observed in the studies over short treatment periods, monitoring localized signs and patient-reported discomfort. Despite comparative trials, the follow-up durations were limited, highlighting changes only over the acute phase, with limited information for long-term outcomes or durability.

---

Evidence for use in Chronic Pelvic Inflammation and Postoperative States

For conditions marked by functional limitations and residual masses, the enzyme preparation was evaluated in supportive clinical trials and non-randomized clinical studies. These studies explored its use in adult patients managing consequences of chronic inflammation like Pelvic Inflammatory Disease (PID) or recovering from abdominal surgery. Studies monitored outcomes such as localized swelling and changes via ultrasound. Observations were recorded within treatment courses not exceeding 10 days. The evidence heterogeneity exists across studies because of the varied conditions. Comparative evidence is lacking, and follow-up durations were limited, meaning long-term outcomes remain uncharacterized regarding relapse risk or the persistence of adhesions.

---

Long-term Studies and Durability of Response

Most available evidence is derived from settings with varying symptom burdens and research exploring short-term symptom changes. The follow-up durations were limited across primary studies, often assessing outcomes only over the 7 to 10-day course of therapy. Therefore, there is limited information for long-term outcomes concerning how durable any initial change may be. Research provides context but not individual predictions about recurrence or the need for subsequent management.

---

Evidence in Specific Patient Populations

The primary research base was conducted among adult patient groups. Data for certain groups remain insufficient. Specifically, evidence is limited concerning the effects and safety profiles of this preparation in children and adolescents. The results apply only to the populations studied, and certainty remains low due to the lack of dedicated research.

---

Areas of Research Uncertainty

A central limitation is that the sample sizes were modest across some trials. The scientific evidence may be heterogeneous because the preparation was studied for such a varied range of conditions. There is limited information for long-term outcomes, particularly concerning the long-term persistence of adhesions. Studies are currently examining how findings help contextualize how patients reported their experience.

Key Studies & References

1. Medicinal Product Distreptaza (Summary of Product Characteristics/Regulatory Data)
2. Streptodornase and Streptokinase - MeSH (Medical Subject Headings) Descriptor and Definition

Common questions about Дистрептаза (FAQ)

---

Q: Is Дистрептаза an antibiotic or an enzyme preparation?

A: Дистрептаза is classified as a combined enzymatic preparation, which belongs to a group of medicines called antithrombotic agents. Its function is based on the localized action of two enzymes, Streptokinase and Streptodornase, which possess the capability to break down fibrin and purulent material. Official classification confirms that its action is enzymatic, not antibiotic.

---

Q: Is it safe to drink alcohol while undergoing treatment with Дистрептаза?

A: Official regulatory documents indicate that no specific negative interactions with alcohol have been formally documented. The main restrictions on use are related to co-administration with specific medications, such as anticoagulants and calcium salts.

---

Q: Are there any known interactions between Дистрептаза and hormonal contraceptives?

A: The official interaction profile lists specific drug contraindications but does not document any known interaction or specific warnings concerning hormonal contraceptives. The main prohibitions are against concurrent use with anticoagulant drugs and calcium salts.

---

Q: Are there any known issues with long-term use of Дистрептаза?

A: Because the medicine is prescribed for short-term use, typically 7 to 10 days, official regulatory information does not contain specific safety data or recommendations for use beyond this duration.

---

Q: Does Дистрептаза require any special preparation before use?

A: The official administration guidelines indicate that the primary preparation is removing the suppository from its protective packaging. Instructions for deep rectal insertion are provided in the 'How to use' section of the product information.

---

Q: Is Дистрептаза manufactured in different strengths?

A: The product is regulated and documented as a single, fixed-dose combination. Each suppository contains 15,000 IU of Streptokinase and 1,250 IU of Streptodornase. No other strengths are officially documented in the product specifications.

---

Q: Are there any dietary restrictions recommended while using Дистрептаза?

A: Official regulatory documents indicate that no specific negative interactions with food or common herbal products are documented. Therefore, no specific dietary restrictions are recommended.

---

Q: Is it normal to feel a change in bowel habits while using Дистрептаза?

A: Official product information lists common adverse reactions, primarily local pain and swelling at the administration site, as well as systemic allergic conditions. Changes in bowel habits are not listed among the officially documented or classified side effects.

---

Q: Does Дистрептаза cause photosensitivity or skin reactions?

A: The documented side effect profile does not list photosensitivity (increased sensitivity to sunlight) as a possible adverse reaction. Local reactions are confined to the site of administration, such such as local pain or swelling.

---

Q: What if I'm allergic to other enzyme products, can I still use Дистрептаза?

A: The product is strictly contraindicated (must not be used) if a patient has a known hypersensitivity to the active ingredients, Streptokinase and Streptodornase, or any of the other excipients in the suppository. The official contraindication is specifically limited to hypersensitivity to these components.

---

Q: Are there any natural substances that interact negatively with Дистрептаза?

A: The regulatory documents restrict co-administration only with anticoagulant drugs and calcium salts. Regulatory sources explicitly state that no interactions with herbal products are documented.

How to Store and Dispose of Дистрептаза (Distreptaza)

Official regulatory documents define strict storage conditions for Дистрептаза suppositories to maintain their stability.

Storage Requirements

• The medicine must be stored in a refrigerator at a temperature range of 2 C to 8 C.
• The product must not be frozen.
• It must be kept out of the sight and reach of children.
• Do not use the medicine after the expiry date shown on the packaging.

Disposal Instructions

Expired or unused Дистрептаза must not be disposed of via wastewater or household waste.

To ensure environmentally responsible disposal, consult a pharmacist on the proper methods for discarding medicines you no longer require.